Shanghai Medicilon Inc. (SHA:688202)
China
· Delayed Price · Currency is CNY 65.75
-1.80 (-2.66%)
At close: Apr 29, 2026
Shanghai Medicilon Revenue
In the year 2025, Shanghai Medicilon had annual revenue of 1.16B CNY with 12.08% growth. Shanghai Medicilon had revenue of 320.10M in the quarter ending December 31, 2025, with 35.62% growth.
Revenue
1.16B
Revenue Growth
+12.08%
P/S Ratio
7.44
Revenue / Employee
495.13K
Employees
1,717
Market Cap
8.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.16B | 125.32M | 12.08% |
| Dec 31, 2024 | 1.04B | -327.89M | -24.01% |
| Dec 31, 2023 | 1.37B | -293.30M | -17.68% |
| Dec 31, 2022 | 1.66B | 491.67M | 42.12% |
| Dec 31, 2021 | 1.17B | 501.31M | 75.28% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Bio-Thera Solutions | 933.69M |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Sino Biological,Inc. | 699.56M |
| Aurisco Pharmaceutical | 1.68B |
| Youcare Pharmaceutical Group | 2.45B |
| Liaoning Chengda Biotechnology | 1.39B |
| Beijing Hotgen Biotech | 404.88M |